Are Weight Loss Drugs Worth It? Here's What the Research Actually Says
Mar 21, 2026 • 9 min read
Published on March 21, 2026 | Updated on March 21, 2026
March 21, 2026
MS, Registered Dietitian, Former President of CT Academy of Nutrition & Dietetics
Weight loss drugs are everywhere right now: your TikTok feed, your doctor's office, your coworker's lunch conversation. And honestly? The results people are seeing with GLP-1 medications like Ozempic, Wegovy, and Mounjaro are real. Clinical trials show that semaglutide alone can help people lose around 12% of their body weight, and tirzepatide pushes that to roughly 18%.
But here's the thing nobody's talking about loudly enough: up to 65% of people stop taking these drugs within the first year.
This is not because they don't work, but is more often due to high out-of-pocket costs, lack of insurance coverage, and side effects. This is because the side effects hit different in real life than they do in a controlled clinical trial. Some people may also choose to come off weight loss drugs because they lost the weight and want to try to keep it off without medication.
So before you (or someone you love) decides to start a GLP-1 medication, here's an honest, research-backed rundown of what the data actually says — including what's common, what's rare, and what we still genuinely don't know yet.
Quick note: This article is for informational purposes only. Weight loss medications should only be prescribed and monitored by a qualified healthcare provider. If you're considering one, please have that conversation with your doctor first.
Short on time? Here's the gist:
The most common side effects are gastrointestinal (nausea, vomiting, constipation, diarrhea), and they're the main reason people stop treatment.
Muscle loss is a real but overlooked risk; protein intake and resistance training can help.
Mood changes and mental health effects have been reported; the evidence is mixed but worth paying individual attention to
A December 2025 study flagged a rare but meaningful link to a serious eye condition called NAION.
Gallbladder disease risk is elevated; the pancreatitis link is less clear-cut than often claimed.
Most people regain around two-thirds of their lost weight within a year of stopping.
Never use unregulated or compounded versions — the FDA has flagged hospitalizations linked to them.
But the thing is: because a few of these are more nuanced than they look, you should consider the context first, just in case it does (or doesn’t) apply to your situation.
GLP-1 receptor agonists (the scientific name for drugs like Ozempic, Wegovy, Mounjaro, and Zepbound) work by mimicking a hormone your body already makes, glucagon-like peptide-1, which tells your brain you've eaten enough. They also stimulate the release of insulin, which can help support healthy blood sugar levels. This process of increasing insulin slows down how quickly food leaves your stomach, helping you feel full for longer.
It's genuinely clever science. But like most things that mess with your body's natural signaling, there are some trade-offs.
→ Check our GLP-1 weight loss guide for more “get to know you” about weight loss drugs.
This is the big one. Gastrointestinal issues are by far the most frequently reported side effect across both clinical trials and real-world users. According to a 2025 review published in Diabetes, Obesity and Metabolism, nausea and digestive problems are the main reasons people stop taking these medications.
A 2025 RAND survey found that about one in five GLP-1 users reported vomiting, and the majority described their overall side effects as mild. Still, "mild" and "not annoying" are two very different things.
Picture this: food sitting heavily in your stomach, that low-grade queasy feeling that shows up uninvited, especially in the first few weeks. It's less "I ate too much" and more "my stomach has simply stopped doing its job," which makes sense given that slowing digestion is literally how the drug works.
The silver lining? These symptoms tend to ease up over time and are usually worse initially when doses are increased. Eating smaller meals, avoiding greasy or spicy foods, and staying upright after eating all help.
Yes, both can occur, because your gut is complicated like that.
Since GLP-1 drugs slow gastric emptying, constipation is a common complaint. Diarrhea can also happen, especially during dose adjustments or if a lot of heavier foods are consumed, such as those high in fat.
Hydration is genuinely important here (and often underestimated). Doctors recommend at least two to three liters of water daily while on these medications to promote more regular, smoother digestion, especially since dehydration can put strain on your kidneys.
Here's one that doesn't get nearly enough airtime. When you lose weight quickly, through any method, your body doesn't just lose fat. It can also break down lean muscle mass.
GLP-1 drugs are no exception, and because the appetite suppression is so strong, some people end up significantly under-eating protein without realizing it. Keeping protein intake up and incorporating resistance training can help preserve muscle while on these medications.
This isn't a reason to avoid the drugs, but it is a reason not to coast on them without paying attention to what you're eating.
GLP-1 drugs affect dopamine and serotonin activity in the brain, the same chemicals that make eating pleasurable. Reducing cravings for high-fat, high-sugar foods is part of how they work. But interfering with those reward pathways can affect mood in some people, particularly if the effect is more profound.
A 2024 study analyzing FDA adverse event reports found an association between semaglutide use and suicidal ideation, though no causal link was established. Other studies have not replicated the finding, and the research community broadly agrees that long-term data is still too limited to draw firm conclusions.
Rapid body weight changes can also affect body image and self-perception in complicated ways. If you're on a GLP-1 medication and notice significant mood shifts, particularly if you have a history of a mood disorder such as depression and anxiety, it’sworth flagging with your doctor.
This is a newer area of research, and the findings are concerning enough to mention.
In a December 2025 study, Professor Guirguis's team analyzed FDA adverse event data and found a meaningful association between semaglutide use and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden vision loss in one eye. The proposed mechanism involves rapid blood sugar changes affecting blood flow to the optic nerve.
The association is notable, but still based on patient reporting rather than controlled lab studies, so it's an area to watch rather than a definitive verdict.
That said, people with pre-existing eye conditions (particularly those related to diabetes) should consult an eye doctor before starting semaglutide.
Rapid weight loss is a known trigger for gallstone formation, and a meta-analysis of 76 randomized controlled trials found GLP-1 users had a 37% higher relative risk of developing gallbladder disease, with risk increasing at higher doses and longer durations.
The pancreatitis link is less clear-cut than it's often portrayed. Early studies raised concerns, but more recent large-scale meta-analyses haven't found a consistent increase in risk for people without prior history. If you have had pancreatitis before, that's a conversation to have with your doctor before starting. Either way, severe upper abdominal pain radiating to your back is a reason to seek care promptly.
This one flies under the radar, but it matters: because GLP-1 drugs delay gastric emptying, there's an increased risk of aspiration (inhaling stomach contents) during surgery.
Guidance on this has actually evolved: the American Society of Anesthesiologists initially recommended pausing GLP-1s before elective procedures, then revised that stance in late 2024 to say most patients can continue, with risk assessed case by case.
Either way, make sure your surgical team knows you're on a GLP-1 drug, even for something as routine as a colonoscopy prep, where bowel preparation can be more complicated.
During animal studies, GLP-1 drugs were associated with thyroid tumors, specifically a rare form called medullary thyroid carcinoma (MTC). The same link hasn't been confirmed in humans, but it's why these medications carry a contraindication for anyone with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2).
This isn't a reason to panic if you don't have that history. It's just one more reason why these aren't over-the-counter supplements, and theyrequire proper prescribing and more stringent, ongoing monitoring.
According to a large-scale analysis of 11 global studies, stopping GLP-1 drugs often leads to significant weight regain.
This isn't a character flaw or a lack of willpower. It's biology. Once the drug is out of your system, hunger signals return, food starts feeling rewarding again, and your body's set point tries to pull you back to your previous weight. The underlying behaviors and patterns that contributed to weight gain in the first place haven't changed.
This is why experts increasingly frame GLP-1 medications as a long-term or even indefinite treatment, similar to how we'd treat high blood pressure or cholesterol. That's a significant commitment, both financially (these drugs remain expensive) and practically.
Here's what makes this whole conversation more layered: real-world results are consistently lower than trial results. In clinical trials, participants are carefully monitored, counselled regularly, and have their medication covered. In everyday life? People skip doses, deal with insurance battles, and often aren't getting the nutrition support they need alongside the medication.
A 2025 narrative review in Diabetes, Obesity and Metabolism found real-world weight loss ranging from 4.4% to 19.5% with semaglutide. That’s a huge variance that comes down to how closely people are able to follow through. It also found discontinuation rates of 20–50% within the first year.
There's also the unregulated market to contend with. The FDA has flagged numerous reports of adverse events (some requiring hospitalization) linked to compounded or counterfeit versions of semaglutide and tirzepatide sold online.
These products can contain incorrect ingredients, inaccurate doses, or no active ingredient at all. If it's not coming from a licensed pharmacy with a valid prescription: skip it.
That's genuinely not a yes-or-no answer, and anyone who tells you it probably has a course to sell you.
For people with significant obesity-related health risks, including cardiovascular disease, type 2 diabetes, and sleep apnea, the benefits of GLP-1 medications are real and well-documented. One major trial found a 20% reduction in serious cardiovascular events among people with obesity and existing heart disease who took semaglutide.
For people looking for a quick fix without addressing nutrition, movement, or the psychological relationship with food?
The math gets harder. Not because you're doing it wrong. Because the drug works best as one tool in a bigger toolkit, not a standalone solution, for best results.
The most common side effects of weight loss drugs like GLP-1s are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These affect most users to some degree in the first couple of months and are the main reason people stop treatment. Fortunately, most people only experience mild side effects that generally improve or resolve after those first few months. Less common but more serious risks include gallbladder disease, mood changes, vision problems, surgical complications, and aspiration during surgery.
Zepbound (tirzepatide) causes the same core side effects as other GLP-1 drugs — nausea, vomiting, diarrhea, constipation, and abdominal pain. GI events may be slightly more frequent at higher doses compared to semaglutide, though overall tolerability is similar. The same risks around gallbladder disease, muscle loss, and anesthesia complications apply.
GLP-1 medications aren't for everyone. They're generally not recommended for people who are pregnant or breastfeeding, have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or a history of pancreatitis. People with severe GI conditions, eating disorders, or significant kidney or liver issues may also be advised against them. Your doctor will review your full health history before prescribing.
For most people, the honest answer is: long-term. GLP-1s work by continuously regulating appetite signals — not by permanently changing how your body manages weight. Studies show that people who stop taking them typically regain a significant portion of lost weight within a year. Stopping should always be a medically guided decision, not something you do once you hit a goal weight.
This article is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional advice or help and should not be relied on to make decisions of any kind. Any action you take upon the information presented in this article is strictly at your own risk and responsibility!
